Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.56 |
| ▸ | FGFR3 | P22607 | 15/20 | 0.56 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384061 | 0.86 | KDR (0.56) | KDRFGFR3 | |
| SCHEMBL3383459 | 0.82 | FGFR3 (0.61) | KDRFGFR3ROCK2 | |
| SCHEMBL3383252 | 0.81 | KDR (0.69) | KDRFGFR3 | |
| SCHEMBL13483161 | 0.80 | WNT3A (0.49) | KDRFGFR3ROCK2 | |
| SCHEMBL3383012 | 0.80 | KDR (0.63) | KDRFGFR3 | |
| SCHEMBL3380736 | 0.80 | KDR (0.50) | KDRFGFR3ATG4B | |
| SCHEMBL3385831 | 0.80 | KDR (0.48) | KDRFGFR3ATG4BROCK2ROCK1 | |
| SCHEMBL3382628 | 0.80 | KDR (0.56) | KDRFGFR3 | |
| SCHEMBL3382983 | 0.79 | KDR (0.72) | KDRFGFR3 | |
| SCHEMBL3383255 | 0.79 | KDR (0.55) | KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128461-B | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI | 2010-12-22 | — | — | CN | disclosed |
| EP-1904494-B1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | LILLY CO ELI (US) | 2010-12-01 | — | — | EP | disclosed |
| CN-101128461-A | Imidazo (1, 2-a) pyridine compounds as VEGF-R2 inhibitors | LILLY CO ELI (US) | 2008-02-20 | — | — | CN | disclosed |